Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

British Journal of Psychiatry

Volumn 198, Issue 6, 2011, Pages 448-456

  Aoyama, Naoko ^a   Théberge, Jean ^a,b   Drost, Dick J ^a,c   Manchanda, Rahul ^a   Northcott, Sandra ^a   Neufeld, Richard W J ^a   Menon, Ravi S ^c   Rajakumar, Nagalingam ^a   Pavlosky, William F ^a,b   Densmore, Maria ^a   Schaefer, Betsy ^a   Williamson, Peter C ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMINE;

ADULT; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; LIMBIC CORTEX; MALE; PARIETAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SOCIAL INTERACTION; TEMPORAL CORTEX; THALAMUS; VOXEL BASED MORPHOMETRY;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL PARTICIPATION; THALAMUS; TIME FACTORS;

EID: 79957984764     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.079608     Document Type: Article

References (33)

1. DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008; 34: 312-21. (Pubitemid 351323343)
2. McClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, Weinberger DR. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res 2006; 148: 121-32. (Pubitemid 44750583)
3. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
4. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
5. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944-6. (Pubitemid 35283267)
6. Théberge J, Al-Semaan, Williamson PC, Menon RS, Neufeld RWJ, Schaefer B, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-3. (Pubitemid 39619619)
7. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res 2009; 108: 69-77.
8. Théberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007; 191: 325-34. (Pubitemid 47555981)
9. Clark JB. N-acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 1998; 20: 271-6.
10. Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 2003; 65: 401-27.
11. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162: 394-6. (Pubitemid 40216226)
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York State Psychiatric Institute, Biometrics Research, 1997.
13. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, 1983.
14. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, 1983.
15. Rosen A, Hadzi-Pavlovic D, Parker G. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 1989; 15: 325-37.
16. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000; 11 (6 Pt 1): 805-21. (Pubitemid 30437668)
17. Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage 2001; 14: 1238-43. (Pubitemid 33124172)
18. Gardner RC, Neufeld RWJ. Use of the simple change score in correlational analyses. Educ Psychol Meas 1987; 47: 849-64.
19. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 846-58. (Pubitemid 40897803)
20. Burbaeva GS, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 675-80. (Pubitemid 36645070)
21. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 1116-8. (Pubitemid 38736001)
22. Wood SJ, Berger GE, Lambert M, Conus P, Velakoulis D, Stuart GW, et al. Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2006; 63: 969-76. (Pubitemid 44330455)
23. Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 2009; 66: 366-76.
24. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 2009; 66: 533-9.
25. Bertrand MC, Sutton H, Achim AM, Malla AK, LePage M. Social cognitive impairments in first episode psychosis. Schizophr Res 2007; 95: 124-33. (Pubitemid 47313633)
26. Olson IR, Plotzker A, Ezzyat Y. The enigmatic temporal pole: A review of findings on social and emotional processing. Brain 2007; 130 (Pt 7): 1718-31. (Pubitemid 47343791)
27. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31-46. (Pubitemid 24071091)
28. Bluhm RL, Miller J, Lanius RA, Osuch EA, Boksman K, Neufeld RW, et al. Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network. Schizophr Bull 2007; 33: 1004-12. (Pubitemid 47216653)
29. Williamson P. Are anticorrelated networks in the brain relevant to schizophrenia? Schizophr Bull 2007; 33: 994-1003.
30. Neufeld RWJ, Boksman K, Vollick D, George L, Carter JR. Stochastic dynamics of stimulus encoding in schizophrenia: theory, testing and application. J Math Psychol 2010; 54: 90-108.
31. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res 1990; 85: 119-46.
32. Miller J, Williamson P, Jensen JE, Manchanda R, Menon R, Neufeld R, et al. Longitudinal 4.0 Tesla (31)P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatr Res Neuroimaging 2009; 173: 155-7.
33. Théberge J, Al-Semaan Y, Drost DJ, Malla AK, Neufeld RW, Bartha R, et al. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatr Res Neuroimaging 2004; 131: 107-14.